drugset / Trial / NCT01134627

Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]

NCT01134627

Phase 2 Terminated 305 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects with relapsing-remitting multiple sclerosis (RRMS).

Timeline

Start
2006-02
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 100 mg Oral